3'-azido-3'-deoxythymidine (AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human immunodeficiency virus type 1 variants

Journal of Virology

Volumn 72, Issue 6, 1998, Pages 4858-4865

  Arts, Eric J ^a,c   Quiñones Mateu, Miguel E ^a   Albright, Jamie L ^a   Marois, James Paul ^b   Hough, Charles ^b   Gu, Zhengxian ^b   Wainberg, Mark A ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; LAMIVUDINE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE; STAVUDINE; VIRUS DNA; ZALCITABINE; ZIDOVUDINE; ZIDOVUDINE 5' TRIPHOSPHATE;

ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DNA SYNTHESIS; DRUG MECHANISM; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS RESISTANCE;

EID: 2642626633     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.6.4858-4865.1998     Document Type: Article

References (48)

1. Arts, E. J., and M. A. Wainberg. 1994. Preferential incorporation of nucleoside analogs after template switching during human immunodeficiency virus reverse transcription. Antimicrob. Agents Chemother. 38:1008-1016.
2. Arts, E. J., J. Mak, L. Kleiman, and M. A. Wainberg. 1994. DNA found in human immunodeficiency virus type 1 particles may not be required for infectivity. J. Gen. Virol. 75:1605-1613.
3. Arts, E. J., J. P. Marois, Z. Gu, S. F. J. Le Grice, and M. A. Wainberg. 1996. Effects of 3′-deoxynucleoside 5′-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type-1 reverse transcription of minus-strand strong-stop DNA. J. Virol. 70:712-720.
4. Arts, E. J., and M. A. Wainberg. 1996. Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrob. Agents Chemother. 40:527-540.
5. Back, N. K., M. Nijhuis, W. Keuken, C. A. Boucher, B. O. Oude Essink, A. B. Kuilenburg, A. H. Gennip, and B. Berkhout. 1996. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 15:4040-4049.
6. Bebenek, K., J. Abbotts, S. H. Wilson, and T. A. Kunkel. 1993. Error-prone polymerization by HIV-1 reverse transcriptase: contribution of template-primer misalignment, miscoding and termination probability to mutational hot spots. J. Biol Chem. 268:10324-10334.
7. Boyer, P. L., C. Tantillo, A. Jacobo-Molina, R. G. Nanni, J. Ding, E. Arnold, and S. H. Hughes. 1994. Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length: the sensitivity of drug-resistant mutants does not. Proc. Natl. Acad. Sci. USA 91:4882-4886.
8. Brun-Vézinet, F., C. Boucher, C. Loveday, D. Descamps, V. Fauveau, J. Izopet, D. Jeffries, S. Kaye, C. Krzyanowski, A. Nunn, R. Schuurman, J. M. Seigneurin, C. Tamalet, R. Tedder, J. Weber, and G. J. Weverling. 1997. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. Lancet 350:983-990.
9. Caliendo, A. M., A. Savara, D. An, K. DeVore, J. C. Kaplan, and R. T. D'Aquila. 1996. Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication. J. Virol. 70:2146-2153.
10. Coates, J. A. V., N. Cammack, H. J. Jenkinson, A. J. Jowett, M. I. Jowett, B. A. Pearson, C. R. Penn, P. L. Rouse, K. C. Viner, and J. M. Cameron. 1992. (-)-2′-deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob. Agents Chemother. 36:733-739.
11. Daluge, S. M., S. S. Good, M. B. Faletto, W. H. Miller, M. H. St. Clair, L. R. Boone, M. Tisdale, N. R. Parry, J. E. Reardon, R. E. Dornsife, D. R. Averett, and T. A. Krenitsky. 1997. 1592U89, a novel carbocylic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob. Agents Chemother. 41:1082-1093.
12. de Jong, M. D., J. Veenstra, N. I. Stilianakis, R. Schuurman, J. M. Lange, R. J. de Boer, and C. A. Boucher. 1996. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine. Proc. Natl. Acad. Sci. USA 93: 5501-5506.
13. Fischl, M. A., D. D. Richman, M. H. Grieco, M. S. Gottlieb, P. A. Volberding, O. L. Laskin, J. M. Leedom, J. E. Groopman, D. Mildvan, R. T. Schooley, M. S. Hirsch, G. G. Jackson, D. T. Track, S. Nusinoff-Lehrman, and the AZT Collaborative Working Group. 1987. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N. Engl. J. Med. 317:185-191.
14. Furman, P. A., J. A. Fyfe, M. H. St. Clair, K. Weinhold, J. L. Rideout, G. A. Freeman, S. N. Lehrman, D. P. Bolognesi, S. Broder, H. Mitsuya, and D. W. Barry. 1986. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. USA 83:8333-8337.
15. Gao, Q., Z. Gu, M. A. Parniak, J. Cameron, N. Cammack, C. Boucher, and M. A. Wainberg. 1993. The same mutation that encodes low-level human immunodeficiency virus type-1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 37:1390-1392.
16. Gray, N. M., C. L. Marr, C. R. Penn, J. M. Cameron, and R. C. Bethel. 1995. The intracellular phosphorylation of (-)-2′-deoxy-3′-thiacytidine (3TC) and the incorporation of 3TC 5′-monophosphate into DNA by HIV-1 reverse transcriptase and human DNA polymerase gamma. Biochem. Pharmacol. 50: 1043-1051.
17. Gu, Z., E. J. Arts, M. A. Parniak, and M. A. Wainberg. 1995. Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2′,3′-dideoxycytidine 5′-triphosphate and other drugs. Proc. Natl. Acad. Sci. USA 92:2760-2764.
18. Gu, Z., Q. Gao, H. Fang, H. Salomon, M. A. Parniak, E. Goldberg, J. Cameron, and M. A. Wainberg. 1994. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immu-nodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 38:275-281.
19. Gu, Z., R. S. Fletcher, E. J. Arts, M. A. Wainberg, and M. A. Parniak. 1994. The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2′,3′-dideoxycytidine, 2′,3′-dideoxy-3′-thiacytidine, and 2′,3′-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro. J. Biol. Chem. 269:28118-28122.
20. Hammer, S. M., D. A. Katzenstein, M. D. Hughes, H. Gundacker, R. T. Schooley, R. H. Haubrich, W. K. Henry, M. M. Lederman, J. P. Phair, M. Niu, M. S. Hirsch, and T. C. Merigan. 1996. A trial comparing nucleoside monotherapy with combination therapy HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N. Engl. J. Med. 335:1081-1090.
21. Harrigan, P. R., I. Kinghorn, S. Bloor, S. D. Kemp, I. Najera, A. Kohll, and B. A. Larder. 1996. Significance of amino acid variation at human immunodeficiency virus type-1 reverse transcriptase residue 210 for zidovudine susceptibility. J. Virol. 70:5930-5934.
22. Huber, H. E., J. M. McCoy, J. S. Seehra, and C. C. Richardson. 1989. Human immunodeficiency virus 1 reverse transcriptase: template binding, processivity, strand displacement synthesis, and template switching. J. Biol. Chem. 262: 4669-4678.
23. Iversen, A. K., R. W. Sharer, K. Wehrly, M. A. Winters, J. I. Mullins, B. Chesebro, and T. C. Merigan. 1996. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J. Virol. 70:1086-1090.
24. Johnson, V. A. 1996. Combination therapy for HIV-1 infection - overview: preclinical and clinical analysis of antiretroviral combinations. Antivir. Res. 29:35-39.
25. Katzenstein, D. A., S. M. Hammer, M. D. Hughes, H. Gundacker, J. B. Jackson, S. Fiscus, S. Rasheed, T. Elbeik, R. Reichman, A. Japour, T. C. Merigan, and M. S. Hirsch. 1996. The relation of virologie and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 per cubic millimeter. N. Engl. J. Med. 335:1091-1098.
26. Kellam, P., C. A. Boucher, and B. A. Larder. 1992. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc. Natl. Acad. Sci USA 89:1934-1938.
27. Kohlstaedt, L. A., J. Wang, J. M. Friedman, P. A. Rice, and T. A. Steitz. 1992. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783-1790.
28. Lacey, S. F., J. E. Reardon, E. S. Furfine, T. A. Kunkel, K. Bebenek, K. A. Eckert, S. D. Kemp, and B. A. Larder. 1992. Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3′-azido-3′-deoxythymidine. J. Biol. Chem. 267: 15789-15794.
29. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155-1158.
30. Larder, B. A., G. Darby, and D. D. Richman. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734.
31. Larder, B. A., S. D. Kemp, and P. R. Harrigan. 1995. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-699.
32. Lavie, A., I. R. Vetter, M. Konrad, R. S. Goody, J. Reinstein, and I. Schlichting. 1997. Structure of thymidylate kinase reveals the cause behind the limiting step in AZT activation. Nature Struct. Biol. 4:601-604.
33. Martin, J. L., J. E. Wilson, R. L. Haynes, and P. A. Furman. 1993. Mechanism of resistance of human immunodeficiency virus type 1 to 2′,3′-dideoxyinosine. Proc. Natl. Acad. Sci. USA 90:6135-6139.
34. Medeiros, A. A. 1997. Evolution and dissemination of β-lactamases accelerated by generations of β-lactam antibiotics. Clin. Infect. Dis. 24:S19-S45.
35. Mesters, J. R., L. A. Zeef, R. Hilgenfeld, J. M. de Graaf, B. Kraal, and L. Bosch. 1994. The structural and functional basis for the kirromycin resistance of mutant EF-Tu species in Escherichia coli. EMBO J. 13:4877-4885.
36. Mitsuya, H., K. J. Weinhold, P. A. Furman, M. H. St. Clair, S. N. Lehrman, R. C. Gallo, D. Bolognesi, D. W. Barry, and S. Broder. 1985. 3′-Azido-3′-deoxythymidine (BWA509V): an antiretroviral agent that inhibits the infectivity and cytopathic effects of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. USA 82:7096-7100.
37. Mosser, A. G., and R. R. Rueckert. 1993. WIN 51711-dependent mutants of poliovirus type 3: evidence that virions decay after release from cells unless drug is present. J. Virol. 67:1246-1254.
38. Rey, D., T. Pi, L. J. Diehl, M. Hughes, T. C. Merigan, and D. Katzenstein. 1996. Do plasma codon 215 mutations explain the failure of ZDV in ACTG 175, abstr., 38. In Abstracts of the Fifth International Workshop on HIV Drug Resistance 1996. Whistler, British Columbia, Canada.
39. Robbins, B. L., J. Greenhaw, M. C. Connelly, and A. Fridland. 1995. Metabolic pathways for activation of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine in human lymphoid cells. Antimicrob. Agents Chemother. 39:2304-2308.
40. Schinazi, R. F., R. M. Lloyd, Jr., M.-H. Nguyen, D. L. Cannon, A. McMillan, N. Ilksoy, C. K. Chu, D. C. Liotta, H. Z. Bazmi, and J. W. Mellors. 1993. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob. Agents Chemother. 37:875-881.
41. Sharma, P. L., P. A. Chatis, A. L. Dogon, D. L. Mayers, F. E. McCutchan, C. Page, and C. S. Crumpacker. 1996. AZT-related mutation Lys70Arg in reverse transcriptase of human immunodeficiency virus type 1 confers decrease in susceptibility to ddATP in in vitro RT inhibition assay. Virology 223:365-369.
42. Shirasaka, T., M. F. Kavlick, T. Ueno, W.-Y. Gao, E. Kujima, M. L. Alcaide, S. Chokekijchai, B. M. Roy, E. Arnold, R. Yarchoan, and H. Mitsuya. 1995. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. USA 92:2398-2402.
43. St. Clair, M. H., J. L. Martin, G. Tudor-Williams, M. C. Bach, C. L. Vavro, D. M. King, P. Kellam, S. D. Kemp, and B. A. Larder. 1991. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253:1557-1559.
44. St. Clair, M. H., C. A. Richards, T. Spector, K. J. Weinhold, W. H. Miller, A. J. Langlois, and P. A. Furman. 1987. 3′-Azido-3′-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob. Agents Chemother. 31:1972-1977.
45. Wainberg, M. A., W. C. Drosopoulos, H. Salomon, M. Hsu, G. Borkow, M. Parniak, Z. Gu, Q. Song, J. Manne, S. Islam, G. Castriota, and V. R. Prasad. 1996. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 271:1232-1285.
46. Wallis, R. S. 1991. PROBIT: a computer program analysis. J. Immunol. Meth. 145:267-268.
47. Wu, J., E. Amandoron, X. Li, M. A. Wainberg, and M. A. Parniak. 1993. Monoclonal antibody-mediated inhibition of HIV-1 reverse transcriptase polymerase activity. Interaction with a possible deoxynucleoside triphosphate binding domain. J. Biol. Chem. 268:9980-9985.
48. Zhang, D., A. M. Caliendo, J. J. Eron, K. M. DeVore, J. C. Kaplan, M. S. Hirsch, and R. T. D'Aquila. 1994. Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 38:282-287.